Abstract 1620: Efficacy and safety of ICIs in lung cancer patients with interstitial pneumonia

Abstract Background: ICIs has demonstrated efficacy against metastatic lung cancer. However, immune-related adverse events can occur, among which pneumonitis is relatively common. Lung cancer patients with interstitial pneumonia (IP) have a higher risk of pneumonitis associated with anticancer therapy. We hypothesized that the benefit of ICIs may outweigh the risks of pneumonitis in patients with lung cancer who have IP. We performed a pilot trial to evaluate the safety of ICIs in lung cancer patients with IP. Methods: Previously treated, inoperable NSCLC patients with IP were enrolled. Patients received anti-PD-1/L1 as monotherapy or in combination with other agents, respectively. Results: A total of 21 lung cancer patients were selected, including 15 (71.4%) male and 6 (28.6%) female with a median age of 62. None experienced drug related nonhematologic grade 3/4 or hematologic grade 4 adverse events in the 12 weeks following the initiation of ICIs treatment. Furthermore, none of the patients had pneumonitis of any grade. At the time of analysis, all patients were alive, and 11 had experienced a partial response. Conclusion: ICIs therapy may be feasible in lung cancer patients with IP. Citation Format: Yan Fu, Fuyu Gong. Efficacy and safety of ICIs in lung cancer patients with interstitial pneumonia [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1620.